Yes, there is a blood test for prostate cancer, and it’s been available for decades. The PSA (prostate-specific antigen) test measures a protein in your blood produced by the prostate gland. It’s the primary blood-based screening tool, but it comes with an important caveat: it can’t tell you definitively whether you have cancer. An elevated PSA signals that something is going on with your prostate, and cancer is only one of several possibilities.
What the PSA Test Actually Measures
PSA is a protein made by both normal and cancerous prostate cells. Everyone with a prostate has some PSA circulating in their blood, so the test isn’t looking for a substance that shouldn’t be there. Instead, it measures how much is present. The higher your PSA level, the more likely prostate cancer is involved, but benign conditions like an enlarged prostate (BPH) and prostatitis (inflammation) also push PSA levels up. That overlap is the core limitation of the test.
Results are reported in nanograms per milliliter (ng/mL), and what counts as “normal” shifts with age. Cleveland Clinic uses these general reference ranges:
- Age 40 to 50: 0 to 2.5 ng/mL
- Age 50 to 60: 2.5 to 3.5 ng/mL
- Age 60 to 70: 3.5 to 4.5 ng/mL
- Age 70 to 80: 4.5 to 5.5 ng/mL
A reading above the range for your age group doesn’t mean you have cancer. It means further evaluation is warranted. Likewise, a normal reading doesn’t completely rule cancer out, since some prostate cancers produce relatively little PSA.
What Can Throw Off Your Results
Several everyday activities can temporarily inflate your PSA, leading to a falsely elevated reading. Ejaculation within 24 hours of the test is one of the most common culprits, so doctors typically advise abstaining the day before your blood draw. Long-distance cycling can also bump PSA levels because the seat puts sustained pressure on the prostate.
Medications matter too. Finasteride, a drug used for hair loss and enlarged prostate, artificially lowers PSA readings. Doctors who know you’re taking it will often double your test result to get a more accurate comparison. If you’re scheduling a PSA test, mention any medications and recent physical activities to your provider so the results can be interpreted correctly.
Newer Blood Tests Beyond Standard PSA
Because PSA alone can’t distinguish between slow-growing cancers, aggressive cancers, and benign conditions, newer blood tests have been developed to add precision. Two of the most widely used are the Prostate Health Index (PHI) and the 4Kscore.
The PHI measures three different forms of PSA-related proteins in your blood, while the 4Kscore combines four blood proteins with clinical factors like age and prior biopsy results. Both tests are designed to better estimate the risk of clinically significant, higher-grade prostate cancer, not just any cancer. In a study published in The Journal of Urology, men who were later found to have more aggressive disease had notably higher PHI scores (median 37.3 versus 27.4) and higher 4Kscores (0.33 versus 0.17) compared to men whose cancer remained low-grade.
These tests are most useful in a specific situation: you already have a borderline or elevated PSA, and you and your doctor are trying to decide whether a biopsy is truly necessary. They help reduce unnecessary biopsies, though their improvement over standard clinical assessment is modest. They’re a refinement, not a replacement.
What Happens After an Elevated PSA
An elevated PSA reading typically leads to a conversation, not an immediate biopsy. Your doctor may recommend repeating the test to confirm the result, since temporary factors could explain a single high reading. If PSA remains elevated, the next step is often an MRI of the prostate, which can identify suspicious areas without an invasive procedure.
If imaging reveals something concerning, a targeted biopsy follows. The biopsy is the only way to confirm prostate cancer. No blood test, no matter how advanced, can provide a definitive diagnosis on its own. The role of blood tests is to help determine who needs that next step and who can safely continue monitoring.
Doctors also track PSA velocity, meaning how quickly your levels rise over time. A sharp upward trend over several tests can be more informative than any single number.
Who Should Get Screened and When
Screening guidelines reflect the tricky balance between catching cancer early and avoiding the harms of overdiagnosis, which means detecting cancers that would never have caused symptoms or shortened someone’s life. The U.S. Preventive Services Task Force recommends that men aged 55 to 69 make an individual decision about PSA screening after discussing the pros and cons with their doctor. For men 70 and older, the Task Force recommends against routine screening because the risks of overdiagnosis and unnecessary treatment generally outweigh the benefits at that age.
For Black men and men with a family history of prostate cancer, the picture is less clear-cut. Both groups face higher risk of developing prostate cancer and of being diagnosed at a younger age. The Task Force acknowledges this increased risk but stops short of issuing a separate recommendation, instead encouraging these men to start the screening conversation earlier. Many urologists suggest that higher-risk men begin discussing PSA testing in their 40s rather than waiting until 55.
There’s no single recommended screening interval. Clinical trials have used schedules ranging from a one-time test to repeat testing every one to four years. More frequent screening and lower PSA thresholds for triggering a biopsy can catch more cancers, but they also increase the rate of overdiagnosis and false alarms.
Liquid Biopsies: A New Frontier
Beyond PSA and its refinements, an entirely different category of blood test is gaining ground. Circulating tumor DNA (ctDNA) testing, sometimes called a liquid biopsy, detects fragments of DNA that tumors shed into the bloodstream. For prostate cancer, the amount of tumor DNA in the blood increases as the disease progresses from localized to metastatic, making it a useful marker of how advanced and aggressive the cancer is.
Right now, ctDNA testing is primarily used in men who already have a prostate cancer diagnosis, particularly advanced disease. It helps guide treatment decisions, monitor whether a therapy is working, and detect emerging drug resistance. It’s not yet a standard screening tool for men who haven’t been diagnosed, but it represents a significant shift toward blood-based cancer monitoring that goes far beyond what PSA can offer.